When a person is diagnosed with Acute Myeloid Leukemia, they will have many good questions. A question such as; how does the disease work, or what is the science behind the condition? How dangerous is the disease? What different types of AML are there and how are they different? What treatment option will work the best? But perhaps one the most helpful questions of them all may be: “How challenging is this disease to cure?”
One of the easiest ways to measure the severity of a condition like Acute Myeloid Leukemia is to define it. A trusted website for disease information, Mayoclinic.org, defines AML as “A cancer of the blood and bone marrow (the spongy tissue inside bones where all of the body’s red blood cells are made.) The disease affects a group of white blood cells within the marrow called the myeloid cells, which normally develop into normal cell types, such as red, white, and platelet blood cells.” In short, AML takes over the body’s new cell production and produces cancerous cells instead of normal blood cells, flooding the body with mutated and deformed cells that are a hindrance to the body’s basic functioning. If left untreated or if treatment is not implemented at an early enough stage, Acute Myeloid Leukemia will eventually cause a large hit on a person’s immune system, organ failure, and death.
The statistics of the disease categorize AML as most common in adults over 65 but is not necessarily rare in any age younger than that. For example, leukemia in general accounts for the most cases of childhood cancer, and AML is the second most common type found in children. On a more positive note, the survival rate for children with AML is between 60-70%. AML is less common in adults because their immune system is the stron...
... middle of paper ...
...Myeloid Leukemia (except Acute Promyelocytic M3). N.p., n.d. Web. 18 Apr. 2014.
"Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia — NEJM."Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia — NEJM. N.p., n.d. Web. 18 Apr. 2014.
"Leukemia Types." Acute Myeloid Leukemia: Overview & Treatment Options. N.p., 01 Jan. 0001. Web. 18 Apr. 2014.
"Adult Acute Myeloid Leukemia Treatment (PDQ®)." National Cancer Institute. N.p., n.d. Web. 16 A"Types of Acute Myeloid Leukemia (AML)." Types of Acute Myeloid Leukemia (AML). N.p., n.d. Web. 18 Apr. 2014.pr. 2014.
"Types of Acute Myeloid Leukemia (AML)." Types of Acute Myeloid Leukemia (AML). N.p., n.d. Web. 18 Apr. 2014.
"Leukemia - Acute Myeloid - AML." Cancer.Net. N.p., n.d. Web. 18 Apr. 2014.
"What Is Hospice (About Hospice)." Home (Hospice Foundation of America). Web. 31 Jan. 2011. .
The public health issue the organization is working to address is to find a cure for blood cancer. At an estimated amount close to 1,012,533 people in the United States are have been diagnosed with leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma. A majority of the diagnosed are living with or are in remission. According to LLS, every four minutes someone new is diagnosed with blood cancer and approximately every 10 minutes dies from blood cancer.
“The word 'leukemia' is a very frightening word. In many instances, it's a killer and it's something that you have to deal with in a very serious and determined way if you're going to beat it” - Kareem Abdul-Jabbar. Many people, including tons of children, fight leukemia every day trying to beat this vicious cancer. Without knowing how leukemia is exactly caused, it puts a damper on how to avoid it.
Schizophrenia: Signs, Types & Causes. (n.d.). Schizophrenia: Signs, Symptoms, Types, Causes, and Effects. Retrieved November 10, 2013, from http://www.helpguide.org/mental/schizophrenia_symptom.htm
Although there are many arguments against embryonic stem cell research, there have already been many success stories because of stem cells. Through bone marrow transplants and stem cell transplants many people survived illnesses against the odds. A bone marrow transplant is when bone marrow from a
- Acute myelogenous leukemia (AML): Is a cancer of the bone marrow and the blood that will progress quickly without treatment. This type of leukemia affects mainly the cells that aren’t fully developed. Therefore, making the cells not carry out their normal functions. With this type of dysfunctional activity in the cells at an early stage, this why it is very important to get care and treatment as soon as possible.
Leukemia like any other cancer is devastating especially when it affects children and especially when they are too young to understand most of what is happening to their bodies. Facts like these are what should be used to motivate researchers and caregivers to help to make the process of treatment and care for patient dealing with disease one that is pleasant and supportive. The research should be taken seriously and it is hoped that in the future a cure can be found and the cause of the disease can be explained. It is also hoped that achievements like those can give families who are coping with disease or who have lost loved ones to the disease can find closure and solace in knowing that other may not have to go through what they have.
Chronic Myeloid leukemia (CML) is a blood and bone marrow disease that slowly progresses. The disease usually occurs in middle aged or older individuals and rarely occurs in children. In CML, an unusually high number of blood stem cells become granulocytes. These granulocytes, also called leukemia cells are irregular in shape and do not develop into healthy white blood cells. Eventually, they concentrate in the blood leaving no room for healthy cells which may lead to infection, anemia, or bleeding. The typical signs of CML include fatigue, fever, night sweats, and weight loss (6).
...matopoietic compartment using integrating vectors particularly need to understand genotoxicity risks in relation to the risks of conventional bone marrow transplantation. A QPL could direct them to ask questions about risk, benefits and survival rates following transplantation at local centres; the prognosis of patients in the different haematopoietic gene therapy trials; the number and status of patients that developed leukaemia in the SCID-X1 gene therapy trials; and whether there are any differences between the proposed vector and the vector used in the SCID-X1 trial and any possible safety developments. This kind of guidance may help patients understand both what is known and unknown about specific applications of gene therapy.
(2013, 04). What are the types of genetic tests?. Your Guide to Understanding Genetic Conditions. Retrieved 04, 2014, from http://ghr.nlm.nih.gov/handbook/testing/uses
Multiple myeloma, also known as myeloma, hematologic cancer, or cancer of the blood is a plasma cell cancer, a type of white blood cell made in the bone marrow that is responsible for creating antibodies. A Multiple myeloma diagnosis means a group of these plasma cells has become cancerous and is multiplying. This cancerous multiplication of plasma cells raises the the level of abnormal proteins in circulating blood, and reduces the space available in the bone marrow for making healthy plasma cells . Health problems caused by multiple myeloma can affect your bones, immune system, kidneys and red blood cell count. The lifetime risk of getting multiple myeloma is 1 in 149 (0.67%).
Kanwar, V.S. (2013, Sep 16). Diseases & Conditions - Medscape Reference. Pediatric Acute Lymphoblastic Leukemia. Retrieved January 13, 2014, from http://emedicine.medscape.com/article/990113-overview#a0156
"Adenosine - What Is Adenosine?" Adenosine - What Is Adenosine? N.p., n.d. Web. 09 Mar. 2014.
"Late Effects of Treatment for Childhood Cancer (PDQ®)." The Canadian Press n.d.: n. pag. - National Cancer Institute. Web. 14 Mar. 2014.
Although the success rate of hematopoietic stem cell therapy was great, patients’ mortality still happened as a result of some factors. Besides from graft-versus-host disease which have previously mentioned, infection contributes for most cases of patient death (Kernan et al, 1993). In allogen...